A group of individual investors has acquired Saneca/Slovakofarma Hlohovec
In this asset deal, a group of private investors has acquired Saneca's cosmetic products portfolio and its pharmaceutical manufacturing plant in Slovakia, from Sanofi. Financial terms of this transaction have not been disclosed.
Saneca (originally Zentiva Hlohovec) is a pharmaceutical contract manufacturing company active in the development, production, registration and distribution of generic medicines and active pharmaceutical ingredients. Saneca also owns portfolio of cosmetic and generic products.
Sanofi is a global integrated healthcare leader engaged in the research, development, manufacturing and marketing of therapeutic solutions.
Oaklins' team in Slovakia advised the buyer in this transaction. The process included due diligence, valuation, negotiation of transaction terms, and selection of new management in the newly purchased entity.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more